Measuring Consumer Exposure Confounds US FDA’s Evaluation Of Cannabinoid Safety In Supplements
Executive Summary
Acting commissioner Woodcock reminds manufacturers and marketers that a consumer’s exposure to cannabidiol and other cannabinoids likely comes from using multiple products daily. “How do you control exposure of people in a nonprescription setting?”
You may also be interested in...
Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products
Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.
To Reach Sweet Spot In CBD Topical Permeation, Sweet Earth Relies On Nanotechnology
Sweet Earth conducts research with NAVCO Pharmaceuticals to confirm previous finding that beneficial effect of CBD is significantly impacted by skin permeation facilitated by nanotechnology. Canadian firm's CBD topicals are formulated with 70 nanometer particles.
Congressional Report Highlights Lack of Mandatory Supplement Listing As DSHEA 2.0 Talks Continue
The Congressional Research Service published a dietary supplements report on 20 September that provides an overview of the industry and current regulatory issues, including ‘limitations’ in the US FDA’s authority over supplements and, in particular, the absence of mandatory product listing.